Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Recent & Breaking News (TSXV:ARCH)

Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST

GlobeNewswire August 18, 2020

Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST

GlobeNewswire August 7, 2020

Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide

GlobeNewswire August 4, 2020

Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide

GlobeNewswire July 28, 2020

Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.

GlobeNewswire July 14, 2020

Arch Biopartners Closes Non-Brokered Private Placement

GlobeNewswire June 30, 2020

Arch Biopartners Arranges Non-Brokered Private Placement

GlobeNewswire June 24, 2020

IIROC Trading Resumption - ARCH

Canada NewsWire June 16, 2020

FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients

GlobeNewswire June 16, 2020

IIROC Trading Halt - ARCH

Canada NewsWire June 16, 2020

Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)

GlobeNewswire June 15, 2020

Grant of Options

GlobeNewswire June 11, 2020

Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)

GlobeNewswire June 8, 2020

Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

GlobeNewswire May 19, 2020

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

GlobeNewswire May 8, 2020

The Top Coronavirus-Related Small-Caps & Bullboards

Stockhouse Editorial April 27, 2020

Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation

GlobeNewswire April 23, 2020

Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model

GlobeNewswire March 31, 2020

ARCH BIOPARTNERS DISCLOSES NEW PATENT FILING FOR NOVEL DRUG CANDIDATES TO PREVENT LUNG INFLAMMATION

GlobeNewswire March 24, 2020

IIROC Trading Resumption - ARCH

Canada NewsWire March 17, 2020